AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results Pharmaceutical Investing
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership Life Science Investing
Telescope Innovations to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub Life Science Investing
Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China Life Science Investing
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference Life Science Investing
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment Life Science Investing
Mariska Hargitay Partners with Bristol Myers Squibb for "Investigating Myeloma" Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease Life Science Investing
U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need Pharmaceutical Investing
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide Pharmaceutical Investing
